Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Common Equity (2018 - 2025)

Bicycle Therapeutics' Common Equity history spans 8 years, with the latest figure at $610.0 million for Q4 2025.

  • For Q4 2025, Common Equity fell 23.09% year-over-year to $610.0 million; the TTM value through Dec 2025 reached $610.0 million, down 23.09%, while the annual FY2025 figure was $610.0 million, 23.09% down from the prior year.
  • Common Equity reached $610.0 million in Q4 2025 per BCYC's latest filing, down from $618.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $873.8 million in Q2 2024 to a low of $142.0 million in Q2 2021.
  • Average Common Equity over 5 years is $437.2 million, with a median of $351.2 million recorded in 2021.
  • Peak YoY movement for Common Equity: dropped 29.32% in 2023, then soared 297.01% in 2024.
  • A 5-year view of Common Equity shows it stood at $346.3 million in 2021, then fell by 21.8% to $270.8 million in 2022, then skyrocketed by 36.98% to $370.9 million in 2023, then skyrocketed by 113.8% to $793.1 million in 2024, then dropped by 23.09% to $610.0 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Common Equity are $610.0 million (Q4 2025), $618.5 million (Q3 2025), and $668.9 million (Q2 2025).